The NHS in the UK is planning to sell anonymized patient data to raise funds, spark research and improve patient outcomes – a controversial move set to benefit companies like Palantir Technologies. Critics are concerned about compromised patient confidentiality and security risks. NHS has an opt-out page for those not wishing to share data and has pledged not to sell data to insurance or marketing firms.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
